Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

The assessment of antimalarial drug efficacy in vivo.

White NJ.

Currently recommended methods of assessing the efficacy of uncomplicated falciparum malaria treatment work less well in high-transmission than in low-transmission settings. There is also uncertainty how to assess intermittent preventive therapies and seasonal malaria chemoprevention (SMC), and Plasmodium vivax radical cure. A pharmacometric antimalarial resistance monitoring (PARM) approach is proposed specifically for evaluating slowly eliminated antimalarial drugs in areas of high transmission. In PARM antimalarial drug concentrations at recurrent parasitaemia are measured to identify outliers (i.e., recurrent parasitaemias in the presence of normally suppressive drug concentrations) and to evaluate changes over time. PARM requires characterization of pharmacometric profiles but should be simpler and more sensitive than current molecular genotyping-based methodologies. PARM does not require parasite genotyping and can be applied to the assessment of both prevention and treatment.

More information Original publication

DOI

10.1016/j.pt.2022.05.008

Type

Journal article

Publication Date

2022-08-01T00:00:00+00:00

Volume

38

Pages

660 - 672

Total pages

12

Addresses

M, a, h, i, d, o, l, -, O, x, f, o, r, d, , T, r, o, p, i, c, a, l, , M, e, d, i, c, i, n, e, , R, e, s, e, a, r, c, h, , U, n, i, t, ,, , F, a, c, u, l, t, y, , o, f, , T, r, o, p, i, c, a, l, , M, e, d, i, c, i, n, e, ,, , M, a, h, i, d, o, l, , U, n, i, v, e, r, s, i, t, y, ,, , B, a, n, g, k, o, k, ,, , T, h, a, i, l, a, n, d, ;, , C, e, n, t, r, e, , f, o, r, , T, r, o, p, i, c, a, l, , M, e, d, i, c, i, n, e, , a, n, d, , G, l, o, b, a, l, , H, e, a, l, t, h, ,, , N, u, f, f, i, e, l, d, , D, e, p, a, r, t, m, e, n, t, , o, f, , M, e, d, i, c, i, n, e, ,, , O, x, f, o, r, d, , U, n, i, v, e, r, s, i, t, y, ,, , O, x, f, o, r, d, ,, , U, K, ., , E, l, e, c, t, r, o, n, i, c, , a, d, d, r, e, s, s, :, , n, i, c, k, w, @, t, r, o, p, m, e, d, r, e, s, ., a, c, .

Keywords

Humans, Plasmodium falciparum, Plasmodium vivax, Parasitemia, Malaria, Malaria, Falciparum, Malaria, Vivax, Antimalarials, Drug Resistance